Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2: a Study on N(6)-Carboxymethyl-lysine, Interleukin 1-α, Dan Superoxide Dismutase in Stratum Corneum

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03815305
• Other study ID #: 441/UN2.F1/ETIK/2018/
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: July 30, 2018
• Est. completion date: June 30, 2019

Study information

• Verified date: January 2019
• Source: Indonesia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the effect of Centella asiatica on hydration status of lower leg skin of DM type 2 patients by measuring SRRC and Skin Capacitance in correlation with AGEs CML, inflammation marker IL-1α, and oxidative stress SOD in stratum corneum.

Description:

This ia a double blind randomized clinical trial on patients diagnosed with DM type 2 with dry skin to assess the effect of Centella asiatica (CA) on dry skin in corellation with AGEs CML, inflammation marker IL-1α, and oxidative stress SOD in stratum corneum after four weeks of treatment. Subjects are divided into three groups of treatment. The first group treated with oral CA and topical CA, second group treated with oral placebo and topical CA, and the last group treated with oral and topical placebo. The total subjects in each treatment groups are 53 subjects. The recruited subjects will be randomized to receive three different treatments, consist of 1. First group (A) will receive combination of oral CA at 2x1100 mg dose and 1% topical CA ointment. 2. Second group (B) will receive oral placebo and topical CA 1% ointment 3. Third group (C) will receive oral placebo and petroleum jelly as topical placebo The recruited subjects will still receive the prescribed treatment for DM type 2. The treatment for dry skin will be administered for 28 days. Randomization done by our supervisor using computer program (RandlistR) by assigning code number for each subjects. The procedures of treatment administration are explained below: 1. Every subject will receive 56 capsules and 10 gram of ointment to be used in 2 weeks period. Subjects will also receive explanation on how to take the drugs 2. Oral drug are taken 2 capsules (@ 550 mg) b.i.d over 12 hours. 3. The ointment is applied two times a day 15 minutes after bath time. 4. The application have to be distributed evenly on a specific 7 x 20 cms area on lower leg. All patients will be given plastic cover to determine the area. 5. The estimation of ointment applied on every leg is as much as ½ FTU or about 0,25 gram. 6. After 2 week period ended, subject will be given the same treatment at follow-up visit.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 159
• Est. completion date: June 30, 2019
• Est. primary completion date: January 12, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 60 Years

Eligibility

Inclusion Criteria:

• Diagnosed with Diabetes Mellitus Type 2

• <60 years old by the end of the study

• suffered from dry skin on lower leg skin area, (minimum score= 3, measured using SRRC)

• agree to not use any skin care product orally or topically on lower leg skin and any other drugs (unless its part of diabetes mellitus management)

• normal ankle brachial index value ranged from 0.91-1.3

Exclusion Criteria:

• the presence of diabetic ulcer on one of patient's foot

• the presence of infection or dermatitis on the experimented foot

• the presence of severe inflammation on the experimented skin (redness score >2 or/and fissure score >2 measured by SRRC or/and total SRRC score ranged from12-16)

• estimated glomerular filtration rate value (eGFR) < 45

• impaired liver function (increased by 2x from upper limit reference for AST/ALT)

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Xerosis Cutis

Intervention

Drug:
• Centella Asiatica Extract
centlla asiatica oral drug at 1100 mg dose
• Topical CA
1% centella asiatica ointment
• Petroleum jelly
vaseline album

Locations

Country	Name	City	State
Indonesia	Universitas Indonesia	Jakarta Pusat	Jakarta

Sponsors (1)

Lead Sponsor	Collaborator
Indonesia University

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Skin Capacitance	SCap measured in (AU)	1 month (evaluated every 2 weeks)
Primary	Change in SOD	Superoxide Dismutase (compared to total protein)	1 month (evaluated every 2 weeks)
Primary	Change in IL-1a	Interleukin-1a (compared to total protein)	1 month (evaluated every 2 weeks)
Primary	Change in AGEs CML	Advanced Glycation End Product, N-(Carboxymethyl)lysine (compared to total protein)	1 month (evaluated every 2 week)
Primary	Change in SRRC	Specified symptom sum score. Measuring dry skin using four variables (scale, roughness, redness, and cracking) in score ranged from 1 to 4 for each variable. The highest the value marks the driest skin	1 month (evaluated every 2 week)